Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$3.19 USD
-0.10 (-3.04%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.20 +0.01 (0.31%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Perspective Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CATX 3.19 -0.10(-3.04%)
Will CATX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CATX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CATX
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
CATX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
Other News for CATX
CATX forms 200 Day Moving Average Support on September 19
CATX Crossed Above 200 Day Moving Average on September 19
CATX: HC Wainwright & Co. Reiterates Buy Rating on Perspective Therapeutics | CATX Stock News
Optimistic Buy Rating for Perspective Therapeutics Driven by Promising Trial Results and Upcoming Catalysts
CATX Fell Below 200 Day Moving Average on September 17